ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1406

The Treatment of Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Voké Kakpovbia1, Maria A. Lopez-Olivo2, Jude Des Bordes3, Robin Christensen4 and Maria E. Suarez-Almazor2, 1Baylor College of Medicine, Houston, TX, 2General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 4The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Meta-analysis and treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: While various studies have looked at possible RA therapies for undifferentiated arthritis (UA), there remains no consensus on optimal management strategies. We undertook a systematic review and meta-analysis to evaluate the efficacy of treatments used in patients with UA.

Methods: We searched in electronic databases (Medline, EMBASE, Web of Science, and The Cochrane Library) with no restrictions up to April 2014. We also searched the clinicaltrials.gov website and the list of references of relevant articles. Two reviewers independently screened citations and evaluated the risk of bias of the included studies.  Data was extracted by one reviewer and cross-checked by another. We performed direct comparison meta-analyses. 

Results:

Eight studies (nine publications) reporting on 931 participants were included. The majority (88%) had a low risk of performance and detection bias, but did not provide details to judge their risk of reporting bias. After reviewing the manuscripts, we decided to include five comparisons: (1) intra-articular triamcinolone combined with Sm-153 PHYP (a radiation synovectomy agent) versus triamcinolone alone, (2) methylprednisolone versus placebo, (3) methotrexate versus placebo/no intervention, (4) infliximab versus placebo, and (5) abatacept versus placebo. Patients on methylprednisolone were less likely to have started a DMARD compared to patients receiving placebo, at 6 months (RR 0.81, 95%CI 0.68-0.96).  Patients on methylprednisolone had less swollen (MD -1.0; -1.6, -0.40) and tender joints (MD -1.0; -2.0, -0.05), improved physician global assessment (MD -6.1; -11.7, -0.52) and quality of life (measured by the EQ5D; MD 0.08; 0.01, 0.15) compared to placebo, at 2 weeks to 12 months; however, compared to placebo there were more patients reporting adverse events in the methylprednisolone group (RR 1.8, 95% CI 1.0-3.3). Patients treated with methotrexate were less likely to develop RA (RR 0.31, 95% CI 0.18-0.53) or have radiographic progression (RR 1.3 95% CI 1.0-1.5) compared to patients treated without methotrexate, at 12-18 months. However, this difference was not observed at 30 months (RR 0.76, 95% CI 0.50-1.1) or 60 months (RR 0.86, 95% CI 0.59-1.3). Higher ACR20 response rates (RR 3.7; 1.3, 10.6), reduced swollen (MD -5.0; -9.8, -0.17) and tender joint counts (MD -13.0; -23.5, -2.5) and fatigue (MD 35.0; 15.6, 54.4) were observed in patients receiving infliximab compared to placebo at 3-6 months.  Similarly, patients receiving abatacept had better outcomes compared to patients receiving placebo including disease remission (RR 2.0; 1.1, 3.9), reduced swollen and tender joint count (RR 4.4; 1.5, 13.1), radiographic (MD -0.31; -0.40, -0.22) and MRI changes (MD -5.0; -7. 6, -2.4), at 6-12 months. No other statistically significant differences were found.

Conclusion: Treatment benefits were observed with all alternatives except for intra-articular use of a radiation agent plus triamcinolone versus triamcinolone alone.  Transient delay of RA development was only observed with methotrexate compared to control.


Disclosure: V. Kakpovbia, None; M. A. Lopez-Olivo, None; J. Des Bordes, None; R. Christensen, None; M. E. Suarez-Almazor, None.

To cite this abstract in AMA style:

Kakpovbia V, Lopez-Olivo MA, Des Bordes J, Christensen R, Suarez-Almazor ME. The Treatment of Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-treatment-of-undifferentiated-arthritis-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-treatment-of-undifferentiated-arthritis-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology